Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Oral Nafithromycin vs Oral Moxifloxacin for Community-Acquired Bacterial Pneumonia in Adults
2016-001246-26Phase 2Completed
- Sponsor
- Wockhardt
- Start
- Aug 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nafithromycin in community acquired pneumonia (CAP) and community-acquired pneumonia (CAP) (2 arms), sponsored by Wockhardt. Primary endpoint: Clinical Response at Day 4 in the ITT population. Started Aug 2016; status: completed.
02
Drugs
nafithromycin
03
Conditions
community acquired pneumonia (CAP)community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2016-001246-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001246-26.